Related Experiment Video

Updated: Jun 2, 2026

Mammosphere Assay Reveals Api5-Induced Stemness in Non-Tumorigenic Breast Epithelial Cell Lines
08:05

Mammosphere Assay Reveals Api5-Induced Stemness in Non-Tumorigenic Breast Epithelial Cell Lines

Published on: February 24, 2026

[Implication of integrin alpha5beta1 in human breast carcinoma apoptosis and drug resistance]

G E Morozevich, N I Kozlova, N A Ushakova

    Biomeditsinskaia Khimiia
    |April 27, 2011
    PubMed

    Insights

    Doxorubicin resistance in breast cancer cells involves alpha5beta1 integrin signaling. Targeting this receptor enhances anoikis and doxorubicin sensitivity by inhibiting Akt and Erk2 kinases.

    Area of Science:

    • Cell Biology
    • Molecular Oncology
    • Biochemistry

    Context:

    • Investigating mechanisms of doxorubicin resistance in human breast carcinoma MCF-7 cells.
    • Comparing drug-sensitive MCF-7 cells with their doxorubicin-resistant counterpart, MCF-7Dox.
    • Observing differential expression of alpha2beta1 integrin and alpha5beta1 receptor in resistant cells.

    Purpose:

    • To elucidate the role of alpha5beta1 integrin in doxorubicin resistance and anoikis in MCF-7Dox cells.
    • To determine the effect of alpha5beta1 integrin silencing on cellular sensitivity to doxorubicin.
    • To explore the impact of alpha5beta1 silencing on key kinase signaling pathways, including Akt and Erk2.

    Summary:

    • Silencing alpha5beta1 integrin in MCF-7Dox cells via alpha5-specific siRNA significantly promoted anoikis (programmed cell death upon detachment).
    • Alpha5beta1 integrin knockdown markedly increased the sensitivity of MCF-7Dox cells to doxorubicin treatment.
    • Downregulation of alpha5beta1 integrin led to a significant inhibition of both Akt and Erk2 kinase activity in resistant breast cancer cells.

    Impact:

    • Suggests alpha5beta1 integrin signaling is a critical mediator of doxorubicin resistance and anoikis evasion.
    • Highlights alpha5beta1 integrin as a potential therapeutic target for overcoming doxorubicin resistance in breast cancer.
    • Indicates that alpha5beta1 integrin-driven cellular signals converge on common pathways involving Akt and Erk2 kinases.

    More Related Videos

    Quantification of Breast Cancer Cell Invasiveness Using a Three-dimensional (3D) Model08:08

    Quantification of Breast Cancer Cell Invasiveness Using a Three-dimensional (3D) Model

    Published on: June 11, 2014

    An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

    An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

    Published on: June 30, 2015

    Related Concept Videos

    Intracellular Signaling Affects Focal Adhesions01:17

    Intracellular Signaling Affects Focal Adhesions

    Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
    Some...
    Activation of Integrins01:15

    Activation of Integrins

    Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
    In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
    Integrins01:10

    Integrins

    Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
    Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
    The Intrinsic Apoptotic Pathway01:31

    The Intrinsic Apoptotic Pathway

    Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...